Bvas Version 3

[Margaret Sigars]

Thesite is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Introduction/objectives: Birmingham vasculitis activity score (BVAS) version 3 (BVAS 3.0) and BVAS/granulomatosis with polyangiitis (BVAS/GPA) are used as indicators of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis. We evaluated the association between these indices and the significance in patients with GPA and microscopic polyangiitis (GPA/MPA).

Methods: We retrospectively reviewed the records of 203 patients with GPA/MPA in our hospital. The correlation between BVAS 3.0 and BVAS/GPA with the five-factor score (FFS) and laboratory data was investigated. The episodes of all-cause mortality, end-stage renal disease, and disease relapse were counted as adverse clinical outcomes. Multivariate Cox hazard analyses were performed to assess the relationships between both indices and patient outcomes.

Background: Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis. Extensive use suggested a need to revise the instrument. The previous version of BVAS has been revised, according to usage and reviewed by an expert committee.

Conclusion: BVAS(v.3) demonstrates convergence with BVAS(v.2), treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein. It is repeatable, reproducible and sensitive to change. The new version of BVAS is validated for assessment of systemic vasculitis.

Birmingham vasculitis activity score (BVAS) version 3 (BVAS 3.0) and BVAS/granulomatosis with polyangiitis (BVAS/GPA) are used as indicators of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis. We evaluated the association between these indices and the significance in patients with GPA and microscopic polyangiitis (GPA/MPA).

We retrospectively reviewed the records of 203 patients with GPA/MPA in our hospital. The correlation between BVAS 3.0 and BVAS/GPA with the five-factor score (FFS) and laboratory data was investigated. The episodes of all-cause mortality, end-stage renal disease, and disease relapse were counted as adverse clinical outcomes. Multivariate Cox hazard analyses were performed to assess the relationships between both indices and patient outcomes.

The BVAS is the most effective validated tool to document disease activity. BVAS v3 consists of a list of items from nine organ systems, which reflect the typical features of active systemic vasculitis. It provides valid definitions for remission and response to therapy as well as flare.

BVAS v3 is valid, reliable and has been widely used in clinical trials in vasculitis to define the responsiveness to various agents including cyclophosphamide, methotrexate, mycophenolate, intravenous immunoglobulin and rituximab.

The BVAS assess disease activity, flare, remission and the chronic effects of systemic vasculitis. The methods are practical and clinically based to enable standardized measurements of disease status, which consist of measuring:

The initial iteration of BVAS, known as BVAS version 1, was introduced in 1994. It was a physician-derived scoring system that aimed to quantify the extent and severity of disease manifestations in different organ systems commonly affected by vasculitis. The score encompassed a range of clinical and laboratory parameters, assigning numerical values to various signs and symptoms indicative of disease activity.

Recognizing the dynamic nature of vasculitis and the importance of capturing changes in disease status over time, subsequent versions of BVAS were developed. BVAS version 2, incorporated modifications to enhance its sensitivity and reliability. This version also introduced the concept of weighting items based on their clinical relevance and impact on patient outcomes.

The evolution of BVAS continued with version 3. This current version has further refined the scoring system and included specific criteria for different types of vasculitis, making it more tailored to the diverse manifestations of these disorders. BVAS version 3 also incorporates input from both physicians and patients, reflecting a broader perspective on disease impact.

Each item should be recorded as present only if the clinician judges it to be due to active vasculitis and intends to give immunosuppressive therapy or escalate immunosuppressive therapy or escalate careful observation of a patient. This concept underpins the use of BVAS v3 because many items listed in BVAS could be present as result of other conditions (including previously active disease, damage, infection, drug toxicity or comorbidity).

It is essential that the items recorded in BVAS v3 should only be recorded after consideration of the cause. This is semi-subjective because some of the evidence is derived from the patient history and physical examination and cannot always be confirmed with more objective testing.

The Luqmani Group have developed comprehensive case-study based training modules for the BVAS and VDI and facilitate the training online or in-person to ensure valid use in studies. They have developed a training website to deliver the case studies with automated feedback and have collaborated with academics and industrial partners to ensure quality control in disease evaluation.

With the 2008 study, Mukhtyar et al. set out to modify and validate version 3 of the BVAS in patients with systemic vasculitis in a prospective cross-sectional study of 313 patients. The number of items was modified from 66 to 56.

The BVAS v3 demonstrates convergence with BVAS v2, treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein results and is a score that is easily reproducible and sensitive to change.

CookiesThe amended Privacy and Electronic Communications Regulations cover the use of cookies on websites and introduce powers for the Information Commissioner to enforce these regulations. This site uses cookies to make parts of the site work better. You don't have to accept these and you may block cookies (by using the settings in your browser), however some website functionality will not then work.No personal information is stored in these cookies For full details of the types of cookies in use by this site please see our 'Legal Info' page.

The Birmingham Vasculitis Activity Score (BVAS) is a validated clinical tool to quantify disease activity in patients with systemic vasculitis. It has been internationally adopted and used by most research groups involved in clinical trials in vasculitis.

The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score. The BVAS form was first published in 1994. Over the past years, there have been a number of changes to further improve the assessment form. Consequently, a newer version has been developed called BVAS V3.

The use of BVAS requires prior training. A training manual is available online at the website of the European Vasculitis Study Group. Even without the training the BVAS is a good aide memoire of the clinical manifestations that need to be looked for at each follow up visit for patients with systemic vasculitis.

This is a Microsoft Excel programme of the current version of the BVAS. The e-form will automatically calculate the activity. Macros will need to be enabled on the user computer for the calculator to function.

This is a downloadable Microsoft Excel based calculator of the regimen used by the Rheumatology department. This regimen has not been validated in any clinical trial, but it is the nearest that we can come to an evidence based regimen. The evidence base for this regimen is derived from several sources referenced below.

The Microsoft Excel programme has separate sheets for PMR and GCA. After selecting the appropriate sheet, enter the patient’s details, weight and date of starting prednisolone treatment. These are the only things that you will be able to modify. The suggested regimen will modify if the patient weighs less than 60 kg. You can round off the regimen to a more practical dosing in the currently empty column “Prednisolone dose in mg/day”. The actual cumulative dose will reflect your actual prednisolone use. You can compare this with the suggested cumulative dose to audit the actual regimen.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chemokines are small secreted substances first discovered in 19779 that have molecular weights ranging between 8 and 10 kDA. Based on their biological behaviour and structure, chemokines are categorized as either possessing a homeostatic and inflammatory role or as CC, CXC, C, and CX3C chemokines according to their distinct cysteine residues10. Chemokines were initially described as chemoattractants that induce cell migration to the location of tissue injury and are responsible for maintaining host immunity against infections11. However, subsequent studies have demonstrated that chemokines exert a broad function in immune system homeostasis and act as critical regulators of inflammatory responses12. Indeed, accumulating evidence demonstrate that chemokines plays an important role in the pathophysiology of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), which are representative autoimmune diseases (AIDs)13,14,15,16. In this context, studies have focused on evaluating chemokine levels and clinical features in AIDs such as RA, SLE, and ankylosing spondylitis (AS). Previous publications by Pandya et al. and Wang et al. identified that circulating CXCL10 levels are a disease activity marker in patients with untreated early RA and AS17,18. Meanwhile, several chemokines were revealed as potential markers of disease severity in SLE and predicted kidney involvement, implying that chemokines could be biological markers reflecting inflammation at the systemic and local levels in AIDs19,20. Similarly, there are investigations that assessed the role of chemokines expression in the circulation in AAV and its subtypes, showing association with clinical phenotypes or disease status21,22,23,24,25,26,27,28,29,30,31. Considering the increasing comprehension of chemokines in the development of AIDs, there is a necessity for enhanced insight into chemokines among patients with MPA/GPA; however, few studies have been conducted to date. Therefore, the present study sought to investigate expression of chemokines attracting monocytes/macrophages and T cells in the sera of patients with MPA/GPA, which were enrolled in a prospective cohort of AAV and to evaluate its correlation with disease activity.

3a8082e126